{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "ORPHAN DRUG|Designated|Treatment of acute myeloid leukemia." in comments (approximate match)
Status:
Investigational
Source:
INN:lucicebtide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04478695: Phase 1 Interventional Terminated Relapsed or Refractory Acute Myeloid Leukemia
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02665065: Phase 3 Interventional Active, not recruiting Acute Myeloid Leukemia
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03224819: Early Phase 1 Interventional Terminated Acute Myeloid Leukemia
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02472977: Phase 1/Phase 2 Interventional Terminated Solid Tumor
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04023526: Phase 2 Interventional Active, not recruiting Leukemia, Myeloid, Acute
(2019)
Source URL:
Class:
PROTEIN
Status:
Designated
Source:
FDA ORPHAN DRUG:855021
Source URL:
Class:
PROTEIN
Status:
Designated
Source:
FDA ORPHAN DRUG:841321
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00074737: Phase 2 Interventional Completed Acute Myelogenous Leukemia
(2004)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT02674763: Phase 1 Interventional Completed Acute Myeloid Leukemia
(2016)
Source URL:
Class:
CONCEPT
